114 related articles for article (PubMed ID: 29515069)
1. [Mixed connective tissue disease with pulmonary hypertension developing in a chronic myeloid leukemia patient on dasatinib treatment].
Watanuki S; Kikuchi T; Toyama T; Abe R; Nakayama H; Karigane D; Shimizu T; Kikuchi J; Matsumoto K; Yasuoka H; Kataoka M; Okamoto S; Mori T
Rinsho Ketsueki; 2018; 59(2):174-177. PubMed ID: 29515069
[TBL] [Abstract][Full Text] [Related]
2. [Reversible dasatinib-related pulmonary arterial hypertension in a CML patient].
Nagasaki J; Aoyama Y; Nomoto Y; Ido K; Ichihara H; Mugitani A
Rinsho Ketsueki; 2016 May; 57(5):618-23. PubMed ID: 27263788
[TBL] [Abstract][Full Text] [Related]
3. [Development of pulmonary arterial hypertension during oral dasatinib therapy for chronic myelogenous leukemia].
Morishita S; Hagihara M; Itabashi M; Ishii Y; Yamamoto W; Numata A; Motohashi K; Matsumoto K; Fujisawa S; Nakajima H
Rinsho Ketsueki; 2016 Aug; 57(8):999-1003. PubMed ID: 27599415
[TBL] [Abstract][Full Text] [Related]
4. Reversible Pulmonary Arterial Hypertension Associated with Dasatinib for Chronic Myeloid Leukemia.
Hong JH; Lee SE; Choi SY; Kim SH; Jang EJ; Bang JH; Park JE; Jeon HR; Oh YJ; Yi JE; Jung HO; Youn HJ; Kim DW
Cancer Res Treat; 2015 Oct; 47(4):937-42. PubMed ID: 25648097
[TBL] [Abstract][Full Text] [Related]
5. [Chronic myeloid leukemia complicated by pulmonary hypertension during dasatinib therapy: a single-center retrospective study].
Edahiro Y; Takaku T; Konishi H; Tsukune Y; Fujioka I; Takasu K; Gotoh A; Daida H; Komatsu N
Rinsho Ketsueki; 2017; 58(11):2213-2218. PubMed ID: 29212971
[TBL] [Abstract][Full Text] [Related]
6. A 59-Year-Old Woman With Shortness of Breath and Chest Pain.
Duvvuri PD; Liu J; Bhardwaj C
Chest; 2020 Aug; 158(2):e65-e69. PubMed ID: 32768078
[TBL] [Abstract][Full Text] [Related]
7. [A Case of Drug-Induced Organizing Pneumonia Caused by Dasatinib].
Sato M; Watanabe S; Aoki N; Asakawa K; Moriyama H; Oshima Y; Koya T; Okazuka K; Kikuchi T
Gan To Kagaku Ryoho; 2018 May; 45(5):851-854. PubMed ID: 30026450
[TBL] [Abstract][Full Text] [Related]
8. [Repeated partially reversible pulmonary arterial hypertension related to dasatinib: a case report and literature review].
Jin J; Xu XM; Wang C
Zhonghua Jie He He Hu Xi Za Zhi; 2016 Feb; 39(2):83-7. PubMed ID: 26879609
[TBL] [Abstract][Full Text] [Related]
9. Pulmonary arterial hypertension in a patient treated with dasatinib: a case report.
Skride A; Sablinskis M; Sablinskis K; Lesina K; Lejnieks A; Lejniece S
J Med Case Rep; 2017 Dec; 11(1):362. PubMed ID: 29287600
[TBL] [Abstract][Full Text] [Related]
10. Dasatinib-induced pulmonary arterial hypertension - A rare late complication.
Ibrahim U; Saqib A; Dhar V; Odaimi M
J Oncol Pharm Pract; 2019 Apr; 25(3):727-730. PubMed ID: 29343154
[TBL] [Abstract][Full Text] [Related]
11. Chronic myelogenous leukemia in chronic phase transforming into acute leukemia under treatment with dasatinib 4 months after diagnosis.
Nakamura Y; Tokita K; Nagasawa F; Takahashi W; Nakamura Y; Sasaki K; Ichikawa M; Mitani K
Int J Hematol; 2016 Mar; 103(3):348-53. PubMed ID: 26662559
[TBL] [Abstract][Full Text] [Related]
12. Dasatinib-Induced Pulmonary Arterial Hypertension.
Orlikow E; Weatherald J; Hirani N
Can J Cardiol; 2019 Nov; 35(11):1604.e1-1604.e3. PubMed ID: 31590985
[TBL] [Abstract][Full Text] [Related]
13. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia.
Rasheed W; Flaim B; Seymour JF
Leuk Res; 2009 Jun; 33(6):861-4. PubMed ID: 18986702
[No Abstract] [Full Text] [Related]
14. Is dasatinib-related pulmonary hypertension a clinical concern?
Szmit S
Future Oncol; 2015 Sep; 11(18):2491-4. PubMed ID: 26278893
[No Abstract] [Full Text] [Related]
15. [Reversible pulmonary hypertension as a consequence of dasatinib treatment in a patient with chronic myeloid leukemia and scleroderma].
Ryczek R; Góra-Tybor J; Betkier-Lipińska K; Cwetsch A
Pol Merkur Lekarski; 2013 Jun; 34(204):342-4. PubMed ID: 23882932
[TBL] [Abstract][Full Text] [Related]
16. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.
Shah NP; Rousselot P; Schiffer C; Rea D; Cortes JE; Milone J; Mohamed H; Healey D; Kantarjian H; Hochhaus A; Saglio G
Am J Hematol; 2016 Sep; 91(9):869-74. PubMed ID: 27192969
[TBL] [Abstract][Full Text] [Related]
17. [Reversible pulmonary arterial hypertension related to dasatinib in the treatment for chronic myelogenous leukemia: a case report and literature review].
Liu B; Wang Y; Mi Y; Wang J
Zhonghua Xue Ye Xue Za Zhi; 2014 Jul; 35(7):581-6. PubMed ID: 25052596
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy and safety of domestic dasatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase].
Yu WJ; Du X; Wang WG; Lou J; Liu P; Meng L; Jin J
Zhonghua Xue Ye Xue Za Zhi; 2020 Apr; 41(4):318-321. PubMed ID: 32447937
[No Abstract] [Full Text] [Related]
19. Clinical features of pulmonary arterial hypertension in patients receiving dasatinib.
Shah NP; Wallis N; Farber HW; Mauro MJ; Wolf RA; Mattei D; Guha M; Rea D; Peacock A
Am J Hematol; 2015 Nov; 90(11):1060-4. PubMed ID: 26284693
[TBL] [Abstract][Full Text] [Related]
20. Reversible pre-capillary pulmonary hypertension due to dasatinib.
Buchelli Ramirez HL; Álvarez Álvarez CM; Rodríguez Reguero JJ; García Clemente MM; Casan Clarà P
Respir Care; 2014 May; 59(5):e77-80. PubMed ID: 24149673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]